Sonoma Pharmaceuticals
And markets a global array of treatments for dermatological conditions and advanced tissue care.
Launch date
Employees
Market cap
AUD5.5m
Enterprise valuation
AUD2m (Public information from Sep 2024)
Share price
$3.83 SNOA
Petaluma California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 18.9m | 18.6m | 12.6m | 13.3m | 12.7m | 16.5m | 20.6m |
| % growth | - | (2 %) | (32 %) | 5 % | (4 %) | 30 % | 25 % |
| EBITDA | (6.1m) | (3.8m) | (6.6m) | (4.4m) | (4.5m) | - | - |
| % EBITDA margin | (32 %) | (20 %) | (52 %) | (33 %) | (36 %) | - | - |
| Profit | (2.9m) | (3.9m) | (5.1m) | (5.2m) | (4.8m) | (3.4m) | (1.6m) |
| % profit margin | (16 %) | (21 %) | (40 %) | (39 %) | (38 %) | (20 %) | (8 %) |
| EV / revenue | - | - | - | 0.3x | 0.2x | 0.2x | 0.2x |
| EV / EBITDA | - | - | - | -1.0x | -0.6x | - | - |
| R&D budget | 1.3m | <1m | <1m | <1m | 1.9m | - | - |
| R&D % of revenue | 7 % | 3 % | 1 % | 2 % | 15 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
$4.6m | Post IPO Equity | ||
| N/A | $1.6m | Post IPO Equity | |
$70.0m | Post IPO Equity | ||
| Total Funding | - | ||
Related Content
Recent News about Sonoma Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.